TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10497456

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms with 12 mg of hyperbaric bupivacaine 0.75%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preservative-free normal saline (0.5 mL with 12 mg of hyperbaric bupivacaine 0.75%)
Number of subjects: 50
Study: 8947070

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg x day(-1)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg x day(-1)
Number of subjects: 229
Study: 1836438

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: YAG laser, Argon laser, Electrocautery
Number of subjects: 15
Study: 7126515

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction plus Federov 4‐loop iris clip lens
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Extracapsular extraction with Binkhorst 2‐loop iridocapsular lens
Number of subjects: 33
Study: 31795162

Group type: EXPERIMENTAL
Intervention: Nutrient-dense (ND) breakfast meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Energy-dense (ED) breakfast meal
Number of subjects: 30
Study: 27763685

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (SEP)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combined treatment (PTA + SEP)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (SEP)
Number of subjects: 139
Study: 26552742

Group type: EXPERIMENTAL
Intervention: Dietary portfolio (n = 159)
Number of subjects: 241

Group type: COMPARATOR
Intervention: DASH-type diet (control n = 82)
Number of subjects: 241
Study: 24388737

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 60
Study: 21084969

Group type: EXPERIMENTAL
Intervention: Work day
Number of subjects: 37
Study: 19177029

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-guided dosing for warfarin therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Traditional dosing for warfarin therapy
Number of subjects: 156
Study: 17640542

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment with combination of antiplatelet and anticoagulant therapy, early coronary angiography, revascularization, and anti-ischemic medical therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive risk-factor control after the acute event.
Number of subjects: 0
Study: 15274397

Group type: EXPERIMENTAL
Intervention: Methotrexate-modulated continuous infusion of 5-fluorouracil (ci5-FU/MTX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Raltitrexed
Number of subjects: 32
Study: 11762659

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 units, five tablets per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (five placebo tablets per day)
Number of subjects: 100
Study: 8994754

Group type: EXPERIMENTAL
Intervention: Cefepime/amikacin
Number of subjects: 353

Group type: COMPARATOR
Intervention: Ceftazidime/amikacin
Number of subjects: 353
Study: 8220143

Group type: EXPERIMENTAL
Intervention: Combination of mitozantrone and ifosfamide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single agent mitozantrone
Number of subjects: 34
Study: 3602025

Group type: EXPERIMENTAL
Intervention: Alizapride (5 mg/kg/day, oral route)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alizapride (intravenous and oral routes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31108355

Group type: EXPERIMENTAL
Intervention: Outdoor areas of public venues
Number of subjects: 17737

Group type: COMPARATOR
Intervention: Outdoor areas around schools
Number of subjects: 17737
Study: 28107540

Group type: EXPERIMENTAL
Intervention: Education + Decision Aid (DA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Education
Number of subjects: 51
Study: 25873152

Group type: EXPERIMENTAL
Intervention: Short-stretch inelastic compression bandage for 24 hours after surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard wool and crepe bandage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Short-stretch inelastic compression bandage
Number of subjects: 50
Study: 23401447

Group type: EXPERIMENTAL
Intervention: Elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2
Number of subjects: 651

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 alone
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Elesclomol plus paclitaxel in patients with normal baseline LDH
Number of subjects: 651

Group type: COMPARATOR
Intervention: Paclitaxel alone in patients with high LDH levels
Number of subjects: 651
Study: 21517230

Group type: EXPERIMENTAL
Intervention: Education based on the Health Belief Model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 0
Study: 18554591

Group type: EXPERIMENTAL
Intervention: Three-gas system (5% O2, 6% CO2, 90% N2)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Two-gas system (19% O2, 6% CO2)
Number of subjects: 396
Study: 17635382

Group type: EXPERIMENTAL
Intervention: fermented milk containing Bifidobacterium animalis DN-173 010
Number of subjects: 274

Group type: COMPARATOR
Intervention: heat-treated yoghurt (control)
Number of subjects: 274
Study: 15217814

Group type: EXPERIMENTAL
Intervention: IC‐Clustering
Number of subjects: 0

Group type: COMPARATOR
Intervention: k‐means method
Number of subjects: 0
Study: 12970637

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9830247

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other groups (non-PTSD)
Number of subjects: 0
Study: 8087352

Group type: EXPERIMENTAL
Intervention: Nasal and oral endotracheal intubation with gastric intubation performed via the same route in Group 1 patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Endotracheal and gastric tubes left in original position in Group 2 patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Transnasal puncture for bacteriologic analysis of maxillary sinus content in Group 3 patients
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group of 45 spontaneously breathing patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Group 2 patients
Number of subjects: 162
Study: 2767860

Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) oral cholera vaccine
Number of subjects: 62285

Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) oral cholera vaccine
Number of subjects: 62285

Group type: COMPARATOR
Intervention: Exclusion of mixed infections with V. cholerae 01
Number of subjects: 62285
Study: 1221432

Group type: EXPERIMENTAL
Intervention: delta9-THC (25 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CBN (50 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: delta9-THC (25 mg) + CBN (50 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30365009

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study: 28170356

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Laparoscopic Roux-Y-Gastric Bypass (LRYGB)
Number of subjects: 217
Study: 25500330

Group type: EXPERIMENTAL
Intervention: EUS-guided hepaticogastrostomy (HPG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: EUS-guided choledochoduodenostomy (CD)
Number of subjects: 49
Study: 23429495

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly with gemcitabine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gemcitabine alone (Control)
Number of subjects: 38
Study: 21420063

Group type: COMPARATOR
Intervention: Sodium chloride (saline group, n = 189)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (bicarbonate group, n = 193)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Sodium chloride (saline group)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (bicarbonate group)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Sodium chloride and sodium bicarbonate
Number of subjects: 382
Study: 19283597

Group type: EXPERIMENTAL
Intervention: PrimeTime
Number of subjects: 145

Group type: COMPARATOR
Intervention: Lunch Buddy
Number of subjects: 145
Study: 17954538

Group type: EXPERIMENTAL
Intervention: Intervention (informing about entitled services)
Number of subjects: 1045
Study: 15534159

Group type: EXPERIMENTAL
Intervention: Nortriptyline combined with transdermal nicotine (nortriptyline started at 25 mg, titrated to 75 mg/d for 12 weeks; transdermal nicotine at 21 mg/d for 8 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (matched placebo for nortriptyline)
Number of subjects: 158
Study: 11575536

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (50 mg/kg bolus followed by 15 mg x kg(‐1) x h(‐1) for 6 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 60
Study: 9778981

Group type: EXPERIMENTAL
Intervention: Professional military training of women
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 110
Study: 7810638

Group type: EXPERIMENTAL
Intervention: Acipimox (antilipolytic agent)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2817186

Group type: EXPERIMENTAL
Intervention: Health Risk Appraisal (HRA)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Self-scored instruments
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Follow-up period (7 to 12 weeks)
Number of subjects: 338
Study: 786686

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (45 mg Zn++) with tetracycline hydrochloride (500 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (45 mg Zn++) with doxycycline chloride (200 mg)
Number of subjects: 7
Study: 31004853

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined tranexamic acid (TXA)
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups (including intravenous, topical, and combined)
Number of subjects: 181
Study: 28911008

Group type: EXPERIMENTAL
Intervention: High quintile of arginine intake
Number of subjects: 7591

Group type: COMPARATOR
Intervention: Low quintile of arginine intake
Number of subjects: 7591

Group type: EXPERIMENTAL
Intervention: Arginine intake (continuous association)
Number of subjects: 7591

Group type: EXPERIMENTAL
Intervention: Arginine intake
Number of subjects: 7591
Study: 26250495

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: WHO Group 3 PH
Number of subjects: 488

Group type: COMPARATOR
Intervention: Subjects with IPF and no PH
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Subjects with IPF and WHO Group 3 PH
Number of subjects: 488
Study: 23200272

Group type: EXPERIMENTAL
Intervention: TMZ 140 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMZ 70 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMZ 140 mg/d and TMZ 70 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16480407

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 133U
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 200U
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Btx‐A) 133U and 200U
Number of subjects: 18
Study: 14512806

Group type: EXPERIMENTAL
Intervention: Rye bran bread (295 g daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wheat bread (275 g daily, control)
Number of subjects: 10
Study: 10599663

Group type: EXPERIMENTAL
Intervention: 350-mm2 Baerveldt implant
Number of subjects: 107

Group type: COMPARATOR
Intervention: 500-mm2 Baerveldt implant
Number of subjects: 107
Study: 8952239

Group type: EXPERIMENTAL
Intervention: Intraoral lidocaine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1651893

Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg/day orally for 7 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rebamipide 10 mg/kg, i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rebamipide 10 mg/kg/hr, i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rebamipide (10, 30, 100, 300 mg/kg, i.p.)
Number of subjects: 6
Study: 10391798

Group type: EXPERIMENTAL
Intervention: Ranitidine (25 patients)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Bicitropeptide (24 patients)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Trimipramine (20 patients)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Sucralfate (29 patients)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (22 patients)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cimetidine (26 patients)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (19 patients)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (28 patients)
Number of subjects: 193
Study: 31240436

Group type: EXPERIMENTAL
Intervention: Urinary microRNA biomarker panel (miR‐6807‐5p, miR‐6856‐5p) combined with H. pylori status
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Urinary microRNA biomarker panel (miR‐6807‐5p, miR‐6856‐5p)
Number of subjects: 306
Study: 27929721

Group type: EXPERIMENTAL
Intervention: 0.1% Sodium Hyaluronate
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 0.15% Sodium Hyaluronate
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate
Number of subjects: 176

Group type: COMPARATOR
Intervention: 0.05% Cyclosporine
Number of subjects: 176
Study: 26087303

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus usual care (UC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 15
Study: 24091274

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 21
Study: 21527577

Group type: EXPERIMENTAL
Intervention: High red meat diet (420 g/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low red meat diet (60 g/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vegetarian diet (0 g/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Medium red meat diet (120 g/d)
Number of subjects: 17
Study: 18298484

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16645173

Group type: EXPERIMENTAL
Intervention: Smoking cessation (quit group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Smoking (smoking control group)
Number of subjects: 32
Study: 14652358

Group type: EXPERIMENTAL
Intervention: Low Sodium (LS) diet (50 mmol Na+/d, >80 mmol K+/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sodium supplementation (NaSp) treatment (120 mmol Na+/d)
Number of subjects: 108
Study: 10992843

Group type: EXPERIMENTAL
Intervention: isoflurane (2.3%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: desflurane (12%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: sevoflurane (4%)
Number of subjects: 81
Study: 8763601

Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Transurethral hyperthermia (TUT)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Transurethral microwave hyperthermia (TUMH)
Number of subjects: 341
Study: 1512151

Group type: EXPERIMENTAL
Intervention: Hyperthermia once a week (54.7% complete response rate)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hyperthermia twice a week (57.8% complete response rate)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Overall treatment (56.3% complete response rate)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Severe complications
Number of subjects: 240
Study: 6609524

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 731

Group type: COMPARATOR
Intervention: Vibratory stimulation, high frequency TENS, low frequency TENS, placebo vibratory stimulation
Number of subjects: 731
Study: 31651302

Group type: EXPERIMENTAL
Intervention: NIATx strategy (active implementation strategy)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 49
Study: 29716897

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo with no lifestyle intervention)
Number of subjects: 26
Study: 26377411

Group type: EXPERIMENTAL
Intervention: Immediate surgery (20 eyes)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Watchful waiting (33 eyes)
Number of subjects: 53
Study: 24148093

Group type: EXPERIMENTAL
Intervention: Executive process training (15 sessions, 45 min/session over 5 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Executive process training
Number of subjects: 59

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 59
Study: 22119204

Group type: EXPERIMENTAL
Intervention: ADT+DE (androgen deprivation therapy + docetaxel-estramustine)
Number of subjects: 413

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Chemotherapy (docetaxel-estramustine)
Number of subjects: 413
Study: 20189770

Group type: EXPERIMENTAL
Intervention: Intervention measures to prevent noncompliance, including limited duration of the study, clear recommendations, power calculation, intensity of the intervention, involvement of the control group, waiting-list control group, and single-consent design nested within an observational study.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrumental variable method applied to estimate the intervention effect among compliers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncompliance occurrence in lifestyle trials.
Number of subjects: 0
Study: 17969201

Group type: EXPERIMENTAL
Intervention: Daclizumab induction, tacrolimus, and MMF (Arm 3)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Tacrolimus and corticosteroids (Arm 1)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Tacrolimus, corticosteroids, and MMF (Arm 2)
Number of subjects: 312
Study: 15755856

Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplementation (1000 mg Ca/d)
Number of subjects: 143
Study: 12149511

Group type: EXPERIMENTAL
Intervention: Saliva IgM and IgA antibodies to E. coli O157 lipopolysaccharide (LPS)
Number of subjects: 22
Study: 10694073

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for urinary incontinence
Number of subjects: 0
Study: 7784112

Group type: EXPERIMENTAL
Intervention: Chest radiograph
Number of subjects: 60
Study: 2327922

Group type: EXPERIMENTAL
Intervention: Double-gloved operating team
Number of subjects: 841

Group type: COMPARATOR
Intervention: Single-gloved operating team
Number of subjects: 841
Study: 386962

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31612335

Group type: EXPERIMENTAL
Intervention: Intrahematomal catheter reaching the ventricles
Number of subjects: 74

Group type: COMPARATOR
Intervention: Catheter placed exclusively in the ICH
Number of subjects: 74
Study: 30585148

Group type: EXPERIMENTAL
Intervention: Non-branded corn-based processed snacks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Animal-source foods
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bread and vetkoek, snacks, and confectionery products
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Healthy foods (fruits and animal-source foods)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Corn-based processed snacks, sweets, lollipops, and biscuits
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nutrient profiling score
Number of subjects: 92
Study: 28306757

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (n=67)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual activity (n=69)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Moderate-intensity exercise training vs Usual activity
Number of subjects: 136
Study: 26275735

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (3 cycles of neoadjuvant chemotherapy: 100 mg/m² cisplatin and 85 mg/m² docetaxel followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 232
Study: 23242470

Group type: EXPERIMENTAL
Intervention: pimecrolimus cream 1%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: mometasone furoate (1 mg/g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: clobetasol propionate 0.05%
Number of subjects: 36

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 36
Study: 21319944

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg and esomeprazole magnesium 20 mg fixed-dose combination (FDC) twice daily for 12 months
Number of subjects: 239
Study: 19190462

Group type: EXPERIMENTAL
Intervention: Leksell Gamma Knife PerfeXion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Leksell Gamma Knife 4C
Number of subjects: 200
Study: 17126628

Group type: EXPERIMENTAL
Intervention: Caloric beverage (increased portion size from 360 g/12 fl oz to 540 g/18 fl oz)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Caloric beverage (increased portion size)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Noncaloric beverages
Number of subjects: 33
Study: 14962399

Group type: EXPERIMENTAL
Intervention: Visually Cued Color‐Shape task
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Auditorily Cued Number‐Numeral task
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Conscious recollection component of the PDP task
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: PDP estimates of conscious memory
Number of subjects: 3